ArticleJournal of orthopaedic surgery and research2025
Long-term aspirin use and perioperative outcomes in lumbar interbody fusion: a population-based study using US national inpatient sample database.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the impact of long-term aspirin use (L-AU) on perioperative outcomes in Lumbar interbody fusion (LIF) using the US National Inpatient Sample (NIS) database.
methodsData from 485,224 LIF patients (2010-2019) were extracted from the NIS. A 1:1 propensity score matching (PSM) was performed to balance baseline characteristics between L-AU and non-L-AU groups. Multivariate logistic regression was used to compare complication risks and healthcare economic indicators.
resultsDespite a higher baseline comorbidity burden in the L-AU group, PSM-adjusted analysis revealed that L-AU significantly increased the risk of acute cerebrovascular events (aOR = 1.334, 95% CI 1.201-1.481, P < 0.001) and was associated with prolonged hospitalization. However, L-AU significantly reduced the risk of prosthetic-related complications (uOR = 0.595, P < 0.001) and orthopedic device-related complications (uOR = 0.682, P < 0.001). Healthcare economic analysis showed that L-AU increased hospitalization costs by $181 (P < 0.001) but shortened length of stay by 0.07 days (P < 0.001).
conclusionL-AU exhibits a dual effect in the perioperative period of LIF, potentially increasing cerebrovascular risk while reducing implant-related complications through anti-inflammatory mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.